Alcon 3Q profit down 18 percent without tax gain
Seattle Times (Free subscription) | 28/10/2009
Eye drug maker Alcon Inc. said Wednesday its profit fell 18 percent in the third quarter compared with a year ago, when it received a large tax benefit.
Alcon, Inc.
Your search relates to more than one category
3Vote!
3Vote!
Alcon 3Q profit down 18 percent without tax gain
Seattle Post-Intelligencer (Free subscription) | 28/10/2009
NEW YORK -- Eye drug maker Alcon Inc. said Wednesday its profit fell 18 percent in the third quarter compared with a year ago, when it received a large tax benefit.
3Vote!
Alcon 3Q profit down 18 percent without tax gain
San Fransisco Chronicle (Free subscription) | 28/10/2009
Eye drug maker Alcon Inc. said Wednesday its profit fell 18 percent in the third quarter compared with a year ago, when it received a large tax benefit. Alcon's profit slipped to $515 million, or $1.71 per share, from $627 million, or $2.07 per share, in the... Sponsored Topics: Tax - Taxation - United States - Accounting - Society and Culture
- Alcon 3Q profit down 18 percent without tax gain - Seattle Times
- Alcon 3Q profit down 18 percent without tax gain - Seattle Post-Intelligencer
3Vote!
Alcon Posts 5.9 Percent Sales Growth for Third Quarter
Business Wire (Free subscription) | 27/10/2009
HUENENBERG, Switzerland--(BUSINESS WIRE)--Alcon, Inc. (NYSE:ACL) reported global sales rose 5.9 percent to $1,614 million for the third quarter of 2009, or a 9.0 percent increase excluding the impact of foreign exchange fluctuations. Net earnings for the third quarter of 2009 were $515 million, or $1.71 per diluted share. Excluding the impact of a $240 million tax benefit related to the...
Click here to see all comments
MAXIDEX DEXAMETHAONE WARNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS. Two days later I was BLIND Use Google and enter EPOCRATES...
3Vote!
South and Central America Ophthalmic Devices Investment Opportunities
bharatbook | 3 hours ago
... end users. - Market shares of all the key competitors including Bausch & Lomb Incorporated, Alcon, Inc., Johnson & Johnson Vision Care, Inc., and Essilor International, amongst others. - Key pipeline products that are set to shape the market, broken down by sector. - Information on the top medical equipment companies in the sector in the country covering business description,
3Vote!
Earnings roundup: CommVault, Alcon
Seattle Post-Intelligencer (Free subscription) | 28/10/2009
Last updated October 28, 2009 3:30 p.m. PTEarnings roundup: CommVault, AlconTHE ASSOCIATED PRESSAmong the earnings stories for Wednesday, Oct. 28, from AP Financial News:OCEANPORT, N.J. -- CommVault Systems Inc. reported a flat fiscal second-quarter profit as rising operating expenses and revenue costs overshadowed an increase in sales.NEW YORK -- Eye drug maker Alcon Inc....
Click here to see all comments
MAXIDEX DEXAMETHASONE WRNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS. Two days later I was BLIND Use Google and enter EPOCRATES...
3Vote!
Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
PR News Wire (Free subscription) | 23/10/2009
LOUISVILLE, Ky., Oct. 23 /PRNewswire/ -- Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements with Alcon Research, Ltd., a wholly-owned subsidiary of Alcon, Inc. (NYSE: ACL). The agreements provide Alcon...
Click here to see all comments
MAXIDEX DEXAMETHASONE WARNING
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS. Two days later I was BLIND Use Google and enter EPOCRATES...
3Vote!
Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
Red Orbit (Free subscription) | 23/10/2009
Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with AlconPosted on: Friday, 23 October 2009, 07:00 CDT LOUISVILLE, Ky., Oct. 23 /PRNewswire/ -- Potentia Pharmaceuticals, a privately-held biotechnology company developing medicines for the treatment of age-related macular degeneration (AMD), announced today that it has entered into licensing and purchase option agreements...
Click here to see all comments
MAXIDEX DEXAMETHASONE WARNING
I had eye surgery and in the post-op pack was MAXIDEX (dexamethasone) drops by ALCON LABS. Two days later I was BLIND Use Google and enter EPOCRATES...
3Vote!
8 HealthCare Stocks With 3%+ Dividends
SeekingAlpha.com (Free subscription) | 29/11/2009
... SQ ( BMY ) Drug Manu. 13 12 4.8% GLAXOSMITHKLINE ( GSK ) Drug Manu. 13 12 4.6% MERCK CO INC ( MRK ) Drug Manu. 10 10 4.2% SANOFI-AVENTIS SA ( SNY ) Drug Manu. N/A 8 3.6% PFIZER INC ( PFE ) Drug Manu. 15 8 3.4% JOHNSON AND JOH ( JNJ ) Drug Manu. 14 13 3.1% NOVARTIS AG ADS ( NVS ) Drug Manu. 17 13 3.1% ABBOTT LAB ( ABT ) Drug Manu. 15 13 2.9% ALCON INC ( ACL ) Medical Instru 23 20 2.6% ASTRAZENECA...
Explore : Alcon, Amgen, AstraZeneca, Biotechnologies, Bristol, Bristol, Drug Manufacturers, Glaxosmithkline, Health Care Services, Health Industries, Johnson and Johnson, Medical Products and Supplies, Medtronic, Merck, Novartis, Novo Nordisk, Pfizer Inc, Pfizer Inc., Sanofi-Aventis, Teva Pharmaceutical Industries, Unitedhealth Group
3Vote!
Options Intelligence Report : Options Activity Analysis For ACL, VIX, FEED, ODP, NRG, NVTL, LVS & MSTR
iStockAnalyst.com (Free subscription) | 30/10/2009
Today's tickers: ACL, VIX, FEED, ODP, NRG, NVTL, LVS & MSTR [More...]
3Vote!
NovaBay to Hold Conference Call to Review Aganocide Data Presented at the Infectious Diseases Society of America Meeting
The Earth Times Online Newspaper (Free subscription) | 28/10/2009
EMERYVILLE, Calif., Oct. 28 -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) will hold a webcast conference call on October 30, 2009 to review preclinical data from a study of Aganocide® product candidates NVC-422 and NVC-612 in a model of onychomycosis, com...
3Vote!
Novartis Raises Sales Forecast
The Wall Street Journal (Free subscription) | 22/10/2009
Novartis raised its full-year sales outlook, although it reported flat third-quarter net profit as higher revenue was offset by charges related to its holdings in Alcon and Roche and as growth slowed in its profitable best-sellers.
Click here to see all comments
MAXIDEX DEXAMETHASONE wArnINg
I had eye surgery and in the post-op pack was MAXIDEX(dexamethasone) drops by ALCON LABS. Two days later I was BLIND Use Google and enter EPOCRATES...